Pharmaceutical Compositions
The present invention relates to pharmaceutical compositions comprising the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the present invention relates to dry powder compositions which exhibit improved stability over time, and methods for producing the same.
1 : A dry powder formulation comprising glycopyrrolate, wherein the formulation is stable over a period of at least 1 year under normal conditions.
2 : A dry powder formulation as claimed in claim 1 , wherein the formulation is stable over a period of at least 2 years.
3 : A dry powder formulation as claimed in claim 1 , wherein the formulation is stable over a period of at least 3 years.
4 : A dry powder formulation as claimed in claim 1 , wherein instability of the formulation is indicated by the formation of hard agglomerates.
5 : A dry powder formulation as claimed in claim 1 , wherein stability of the formulation is indicated by consistent good fine particle fraction or fine particle dose values.
6 : A dry powder formulation as claimed in claim 5 , wherein the fine particle fraction of the powder is consistently at least about 30%.
7 : A dry powder formulation as claimed in claim 6 , wherein the fine particle fraction of the powder is consistently at least about 40%.
8 : A dry powder formulation as claimed in claim 1 , wherein stability of the formulation is achieved by preventing or reducing the uptake of moisture by the formulation.
9 : A dry powder formulation as claimed in claim 1 , wherein the glycopyrrolate is micronised.
10 : A dry powder formulation as claimed in claim 9 , wherein the glycopyrrolate is conditioned during or following micronisation to reduce the tendency of the formulation to absorb moisture.
11 : A dry powder formulation as claimed in claim 10 , wherein the conditioning involves controlled exposure of the glycopyrrolate to moisture.
12 : A dry powder formulation as claimed in claim 10 , wherein the conditioning involves disruption of any solid bridges formed during or following micronisation.
13 : A dry powder formulation as claimed in claim 1 , wherein the formulation further comprises a force control agent which is capable of reducing cohesion between the fine particles in the formulation.
14 : A dry powder formulation as claimed in claim 13 , wherein the force control agent also acts as a surfactant.
15 : A dry powder formulation as claimed in claim 13 , wherein the force control agent prevents the ingress of moisture into the formulation.
16 . (canceled)
17 : A dry powder formulation as claimed in claim 1 , wherein the formulation is stored in packaging made from a material which has a moisture content of less than 10%.
18 : A dry powder formulation as claimed in claim 17 , wherein the packaging material has a moisture content of less than 5%.
19 : A dry powder formulation as claimed in claim 17 , wherein the packaging material has a moisture content of less than 3%.
20 : A dry powder formulation as claimed in claim 17 , wherein the packaging is an HPMC capsule.
21 : A dry powder formulation as claimed in claim 1 , wherein the formulation is stored in packaging which is capable of preventing the ingress of moisture form external sources.
22 : A dry powder formulation as claimed in claim 21 , wherein the packaging is a foil sealed blister.
23 : A dry powder formulation as claimed in claim 17 , wherein the packaging is itself protected from the ingress of moisture from external sources.
24 : A dry powder inhaler device comprising a dry powder formulation as claimed in claim 1 .
25 : A method of preparing a dry powder formulation as claimed in claim 1 , wherein the glycopyrrolate is micronised and the micronisation process is performed under conditions which reduce the formation of amorphous material and/or wherein the glycopyrrolate is conditioned to reduce the amorphous material content.
27 : A method as claimed in claim 26 , wherein the conditioning involves controlled exposure of the glycopyrrolate to moisture.
28 : A method as claimed in claim 26 , wherein the conditioning involves disruption of any solid bridges formed during or immediately following micronisation.
29 : A method as claimed in claim 25 , wherein a force control agent which is capable of reducing cohesion between the fine particles in the formulation is added to the glycopyrrolate.
30 . A dry powder formulation as claimed in claim 13 , wherein the force control agent is magnesium stearate, one or more amino acids or their derivatives, lecithin or phospholipids
31 : A dry powder formulation as claimed in claim 30 , wherein the amino acid is leucine, lysine, arginine, histidine or cysteine, or derivatives thereof.